[go: up one dir, main page]

WO2008110872A3 - Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses - Google Patents

Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses Download PDF

Info

Publication number
WO2008110872A3
WO2008110872A3 PCT/IB2007/004522 IB2007004522W WO2008110872A3 WO 2008110872 A3 WO2008110872 A3 WO 2008110872A3 IB 2007004522 W IB2007004522 W IB 2007004522W WO 2008110872 A3 WO2008110872 A3 WO 2008110872A3
Authority
WO
WIPO (PCT)
Prior art keywords
solvent
agent
composition
group
nitric oxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2007/004522
Other languages
French (fr)
Other versions
WO2008110872A2 (en
Inventor
Dov Tamarkin
Meir Eini
Doron Friedman
Tal Berman
Alex Besonov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Foamix Ltd
Original Assignee
Foamix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foamix Ltd filed Critical Foamix Ltd
Publication of WO2008110872A2 publication Critical patent/WO2008110872A2/en
Anticipated expiration legal-status Critical
Publication of WO2008110872A3 publication Critical patent/WO2008110872A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a foamable therapeutic composition comprising: (a) a therapeutically effective concentration of at least one active agent selected from the group consisting of a channel agent, a cholinergic agent, and a nitric oxide donor; and (b) a foamable carrier comprising: i. about 50% to about 98% of a solvent selected from the group consisting of water; a hydrophilic solvent; a hydrophobic solvent; a potent solvent; a polar solvent, a silicone, an emollient, and mixtures thereof; ii. 0% to about 48% of a secondary solvent selected from the group consisting of water; a hydrophilic solvent; a hydrophobic solvent; a potent solvent; a polar solvent, a silicone, an emollient, a co-solvent, a penetration enhancer and mixtures thereof; iii. a surface-active agent; iv. about 0% to about 5% by weight of at least one polymeric agent; and v. a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition; wherein the composition is housed in a container and is substantially flowable, and which upon release expands to form a breakable foam; and wherein the foamable carrier is selected to generate a foam of good to excellent quality. The invention further provides a method of treating, alleviating or preventing a disorder of mammalian subject, comprising administering such a composition to an afflicted target site.
PCT/IB2007/004522 2006-06-23 2007-06-22 Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses Ceased WO2008110872A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81594806P 2006-06-23 2006-06-23
US60/815,948 2006-06-23

Publications (2)

Publication Number Publication Date
WO2008110872A2 WO2008110872A2 (en) 2008-09-18
WO2008110872A3 true WO2008110872A3 (en) 2009-06-25

Family

ID=39705041

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/004522 Ceased WO2008110872A2 (en) 2006-06-23 2007-06-22 Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses

Country Status (1)

Country Link
WO (1) WO2008110872A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8741265B2 (en) 2002-10-25 2014-06-03 Foamix Ltd. Penetrating pharmaceutical foam
WO2019175290A1 (en) 2018-03-13 2019-09-19 Beckley Canopy Therapeutics Limited Cannabis or cannabis derived compositions for promoting cessation of chemical dependence

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
JP2006505583A (en) 2002-10-25 2006-02-16 フォーミックス エルティーディー． Cosmetic and pharmaceutical foam
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
DK1871433T3 (en) 2005-03-24 2009-08-10 Nolabs Ab Cosmetic treatment with nitric oxide, device for performing this treatment and manufacturing process therefor
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
WO2009090558A2 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
WO2010125470A2 (en) 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9919072B2 (en) 2009-08-21 2018-03-20 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
BR112012003792B1 (en) 2009-08-21 2020-05-19 Novan Inc topical composition, and, use of topical composition
MX359879B (en) 2009-10-02 2018-10-12 Foamix Pharmaceuticals Ltd TOPICAL COMPOSITIONS OF TETRACICLINE.
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
IT1397000B1 (en) * 2009-11-12 2012-12-20 Antropoli USE OF A PREPARATION BASED ON NIFEDIPINE FOR THE TREATMENT OF VAGINISM
WO2013006613A1 (en) 2011-07-05 2013-01-10 Novan, Inc. Methods of manufacturing topical compositions and apparatus for same
JP6277124B2 (en) 2011-07-05 2018-02-07 ノヴァン，インコーポレイテッド Topical composition
WO2013067591A1 (en) * 2011-11-10 2013-05-16 Relevare Australia Pty Ltd Topical formulations for pain management
AU2013232576B2 (en) 2012-03-14 2016-09-01 Ligand Pharmaceuticals Incorporated Nitric oxide releasing pharmaceutical compositions
US9855211B2 (en) 2013-02-28 2018-01-02 Novan, Inc. Topical compositions and methods of using the same
US10517817B2 (en) 2013-05-09 2019-12-31 Syk Technologies, Llc Deep topical systemic nitric oxide therapy apparatus and method
KR102428738B1 (en) 2013-08-08 2022-08-02 노반, 인크. Topical compositions and methods of using the same
US10206947B2 (en) 2013-08-08 2019-02-19 Novan, Inc. Topical compositions and methods of using the same
AU2015258472B2 (en) 2014-05-15 2020-05-21 Grunenthal Gmbh Device and formulation for topical treatment of pain affecting the vulvar area of the female human genital organ
EP3698775A1 (en) 2014-07-11 2020-08-26 Novan Inc. Topical antiviral compositions and methods of using the same
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
WO2016010988A1 (en) 2014-07-14 2016-01-21 Novan, Inc. Nitric oxide releasing nail coating compositions, nitric oxide releasing nail coatings, and methods of using the same
US9895311B2 (en) * 2014-09-25 2018-02-20 Pharmiva Ab Foam-forming compositions and methods for delivering an active to a body cavity
US10849864B2 (en) 2015-07-28 2020-12-01 Novan, Inc. Combinations and methods for the treatment and/or prevention of fungal infections
DK3407900T3 (en) 2016-01-27 2024-04-02 Syk Tech Llc Apparatus for topical application of nitrous oxide and methods
JP7090549B2 (en) 2016-03-02 2022-06-24 ノヴァン，インコーポレイテッド Therapeutic compositions for inflammation and their treatment methods
CN109310630A (en) 2016-04-13 2019-02-05 诺万公司 Compositions, systems, kits and methods for treating infections
CA2978573A1 (en) 2016-09-08 2018-03-08 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
EP3758679A4 (en) 2018-03-01 2021-12-15 Novan, Inc. NITRIC OXIDE RELEASING SUPPOSITORIES AND THEIR METHODS OF USE
FR3092247B1 (en) * 2019-01-31 2022-07-08 Oreal Cosmetic composition comprising anti-hair loss active agents, thickening polymers, nonionic surfactants and propellants, and method for cosmetic treatment
EP3980032A1 (en) 2019-06-04 2022-04-13 Thirty Respiratory Limited Methods and compositions for generating nitric oxide and uses thereof to deliver nitric oxide via the respiratory tract
EP3980373A1 (en) 2019-06-04 2022-04-13 Thirty Holdings Limited Methods and compositions for generating nitric oxide and uses thereof
WO2021214440A1 (en) 2020-04-23 2021-10-28 Thirty Respiratory Limited Nitric oxide or nitric oxide releasing compositions for use in treating sars-cov and sars-cov-2
CN115768413B (en) 2020-04-23 2025-10-24 三十呼吸有限公司 Methods and compositions for treating and combating tuberculosis
CN112402615A (en) * 2020-11-11 2021-02-26 长沙晶易医药科技有限公司 Compound external preparation for treating alopecia areata and preparation method thereof
WO2022150415A1 (en) * 2021-01-06 2022-07-14 The Penn State Research Foundation Methods and materials for treating hair loss
BR102021003531A2 (en) * 2021-02-24 2022-08-30 Eurofarma Laboratorios S.A. FOAMBLE TOPICAL PHARMACEUTICAL COMPOSITION
CN113180060B (en) * 2021-05-10 2022-06-17 西南大学 A kind of artesunolide acaricide preserved at normal temperature and preparation method thereof
CN114870016B (en) * 2022-04-21 2023-05-26 上海博悦生物科技有限公司 Micro-emulsion foaming agent of JAK inhibitor and application thereof
US12268677B2 (en) 2022-04-27 2025-04-08 The Penn State Research Foundation 4-aminopyridine (4-AP) and bone morphogenetic protein 2 (BMP-2)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001863A1 (en) * 1986-09-12 1988-03-24 The Upjohn Company Foams for delivery of minoxidil
WO2003055454A1 (en) * 2001-12-21 2003-07-10 Ponsus Pharma Ab New composition
US20050031547A1 (en) * 2003-08-04 2005-02-10 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
WO2005018530A2 (en) * 2003-08-25 2005-03-03 Foamix Ltd. Penetrating pharmaceutical foam
US20050079139A1 (en) * 2003-10-11 2005-04-14 Jacques Elizabeth Joan Minoxidil pharmaceutical foam formulation
US20050271596A1 (en) * 2002-10-25 2005-12-08 Foamix Ltd. Vasoactive kit and composition and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001863A1 (en) * 1986-09-12 1988-03-24 The Upjohn Company Foams for delivery of minoxidil
WO2003055454A1 (en) * 2001-12-21 2003-07-10 Ponsus Pharma Ab New composition
US20050271596A1 (en) * 2002-10-25 2005-12-08 Foamix Ltd. Vasoactive kit and composition and uses thereof
US20050031547A1 (en) * 2003-08-04 2005-02-10 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
WO2005018530A2 (en) * 2003-08-25 2005-03-03 Foamix Ltd. Penetrating pharmaceutical foam
US20050079139A1 (en) * 2003-10-11 2005-04-14 Jacques Elizabeth Joan Minoxidil pharmaceutical foam formulation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8741265B2 (en) 2002-10-25 2014-06-03 Foamix Ltd. Penetrating pharmaceutical foam
WO2019175290A1 (en) 2018-03-13 2019-09-19 Beckley Canopy Therapeutics Limited Cannabis or cannabis derived compositions for promoting cessation of chemical dependence

Also Published As

Publication number Publication date
WO2008110872A2 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
WO2008110872A3 (en) Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses
WO2006003481A3 (en) Oleaginous pharmaceutical and cosmetic foam
WO2009090495A3 (en) Oil and liquid silicone foamable carriers and formulations
WO2009098595A3 (en) Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
DK2494959T3 (en) Foam Bart dicarboxylsyrebærestof and pharmaceutical compositions thereof
US20110052506A1 (en) Stable Aerosol Topical Foams Comprising a Hypochlorite Salt
ES2918299T3 (en) High oil content emollient spray foam compositions
CA2752070C (en) Foamable benzoyl peroxide compositions for topical administration
US8652443B2 (en) Foamable microemulsion compositions for topical administration
WO2008075207A3 (en) Anti-infection augmentation foamable compositions and kit and uses thereof
WO2007039825A3 (en) Saccharide foamable compositions
TW200420303A (en) Clindamycin phosphate foam
US20120148516A1 (en) Tandem Hypochlorite-Barrier Repair Therapy for the Treatment of Eczema
WO2007023396A3 (en) Vasoactive kit and composition and uses thereof
ZA200510388B (en) Foamable pharmaceutical compositions and methods for treating a disorder
WO2007085899A3 (en) Foamable arthropocidal composition for tropical application
WO2008152444A3 (en) Foamable waterless compositions with modulating agents
WO2007050543A3 (en) Topical pharmaceutical foam composition
WO2007007198A3 (en) Retinoid immunomodulating kit and composition and uses thereof
WO2013067271A2 (en) Stable dermatological aerosol foams utilizing reactive propellants
ES2093587T3 (en) NEW FOAM COMPOSITIONS, IN PARTICULAR FOR RECTAL FOAMS, AND FOAMS SO OBTAINED.
IE45321B1 (en) Sprayable germicidal foam compositions
MX2023003754A (en) A pharmaceutical formulation for pressurised metered dose inhaler.
AR055591A1 (en) A SKIN PROTECTIVE TOPIC COMPOSITION AND ITS USE
WO2003070194A3 (en) Amino acid and peptide-modified forms of glucocorticoids

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07872837

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07872837

Country of ref document: EP

Kind code of ref document: A2